Identification of imatinib-resistant long non-coding RNAs in gastrointestinal stromal tumors.
gastrointestinal stromal tumor
hypoxia-inducible factor-1
imatinib mesylate resistance
long non-coding RNAs
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
09
11
2017
accepted:
06
11
2018
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
25
1
2019
Statut:
ppublish
Résumé
Long non-coding RNAs (lncRNAs) are an abundant RNA species that belong to the competing endogenous RNA network, which serves a critical role in the development, diagnosis and progression of diseases. Using chip technology, the current study analyzed the expression of lncRNAs in paired normal gastric tissues, primary gastrointestinal stromal tumor (GIST) tissues and GIST tissues resistant to imatinib mesylate. Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to predict potential tumorigenesis and drug resistance mechanisms. The hypoxia-inducible factor-1 pathway was identified as a putative mediator of drug resistance. To the best of our knowledge, the current study was the first to investigate the role of lncRNAs in imatinib mesylate-resistant GISTs and primary GISTs using chip technology. An association was revealed between lncRNA expression and imatinib mesylate resistance. In summary, the current study identified a panel of dysregulated lncRNAs that may serve as potential biomarkers or drug targets for GISTs, particularly secondary imatinib-resistant GISTs.
Identifiants
pubmed: 30675294
doi: 10.3892/ol.2018.9821
pii: OL-0-0-9821
pmc: PMC6341907
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2283-2295Références
Histol Histopathol. 2000 Oct;15(4):1293-301
pubmed: 11005253
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
J Clin Oncol. 2003 Dec 1;21(23):4342-9
pubmed: 14645423
Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
pubmed: 15451219
Cancer Cell. 2006 Nov;10(5):413-23
pubmed: 17097563
Nat Rev Cancer. 2008 Mar;8(3):180-92
pubmed: 18273037
Nat Rev Cancer. 2008 Nov;8(11):865-73
pubmed: 18923434
Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14391-6
pubmed: 19706526
Oncogene. 2010 Feb 4;29(5):625-34
pubmed: 19946328
Nature. 2010 Apr 15;464(7291):1071-6
pubmed: 20393566
Development. 2010 Aug 1;137(15):2493-9
pubmed: 20573698
Drug Resist Updat. 2011 Jun;14(3):191-201
pubmed: 21466972
Nat Rev Cancer. 2011 Dec 15;12(1):9-22
pubmed: 22169972
Cancer Res. 2012 Mar 1;72(5):1126-36
pubmed: 22258453
Anat Cell Biol. 2012 Jun;45(2):73-8
pubmed: 22822460
Nature. 2013 Jan 10;493(7431):231-5
pubmed: 23201690
Cell. 2013 Jan 31;152(3):570-83
pubmed: 23352431
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3387-92
pubmed: 23401553
Exp Biol Med (Maywood). 2014 May 8;239(7):779-792
pubmed: 24812122
Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):298-304
pubmed: 25446072
Cancer Cell. 2014 Nov 10;26(5):722-37
pubmed: 25517750
Med Oncol. 2015 Apr;32(4):111
pubmed: 25757539
Oncotarget. 2016 Jan 12;7(2):1367-79
pubmed: 26587973
Oncotarget. 2016 Nov 15;7(46):75307-75318
pubmed: 27659532
DNA Cell Biol. 2017 Jan;36(1):18-25
pubmed: 27854515
Hematology. 2017 May;22(4):208-216
pubmed: 27875938
J Biomed Sci. 2017 Aug 8;24(1):53
pubmed: 28789687
Am J Transl Res. 2018 Jan 15;10(1):274-282
pubmed: 29423012
Science. 1998 Jan 23;279(5350):577-80
pubmed: 9438854